NCT01468467View on ClinicalTrials.gov

A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Leukemia, Myeloid, Acute
Interventions
DRUG

AC220

Oral Liquid

Trial Locations (5)

55455

University of Minnesota, Minneapolis

60611

Northwestern University, Chicago

77030

M.D. Anderson Cancer Center, Houston

91010

City of Hope, Duarte

98109

Seattle Cancer Care Alliance, Seattle

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
collaborator

Ambit Biosciences Corporation

INDUSTRY

lead

Daiichi Sankyo

INDUSTRY